Logo

SeqBiome: Marcus Claesson, Paul Cotter, Brad Wrigley

Jul 24, 2020

University College Cork spinout SeqBiome announced its management team this week. Marcus Claesson is the company's CEO, Paul Cotter is the firm's chief technology officer, and Brad Wrigley is executive director.

Claesson is a principal investigator at APC Microbiome Ireland. He has a PhD in bioinformatics from the National University of Ireland and an MSc in bioinformatics, as well as a BSc in chemical engineering and physics, from Chalmers University of Technology in Gothenburg, Sweden.

Cotter is head of food biosciences at Teagasc and a principal investigator with APC Microbiome Ireland, Vistamilk SFI Centres, and Food for Health Ireland. He holds PhD and BSc degrees in microbiology from University College Cork.

Wrigley has been working with several startup and spinout companies. He has more than 20 years of experience as a director, entrepreneur, investor, and CEO in government and industry, including at Accenture, Dell EMC, and Virtustream.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.